Mon - Fri 09:00-18:00 0207 060 3773
Email info@boundarycapital.com

Day

October 12, 2017
What Investment has published the latest news from Boundary Capital’s portfolio company AB Polyblok. Boundary Capital investment company AB-Polyblok has today filed a patent application following the results of in-vitro & in-vivo experiments that have shown that their drug appears to reverse the effects of the key misfolded proteins associated with all three dementia diseases...
Read More

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Cases